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DIALYSIS – TRANSPLANTATION
Regular ultrasonographic screening significantly prolongs
patency of PTFE grafts
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Third Department of Internal Medicine; and Department of Cardiovascular Surgery, General University Hospital and First School
of Medicine, Charles University, Prague, Czech Republic
Regular ultrasonographic screening significantly prolongs pa-
tency of PTFE grafts.
Background. Polytetrafluoroethylene (PTFE) dialysis grafts
have considerably shorter patency than native arteriovenous
fistulas, despite the use of a complex of screening monitoring
methods (venous pressure, access flow). PTFE grafts are used
often in subjects with depleted subcutaneous veins after pre-
vious abandoned accesses, so keeping the access patent is cru-
cial. We hypothesized that regular duplex Doppler ultrasound
screening for access stenoses, together with their sooner treat-
ment, would prolong PTFE graft patency.
Methods. We performed a randomized, prospective study of
PTFE grafts’ cumulative patency in 192 subjects. In group 1,
regular ultrasound examinations performed every 3 months was
added to traditional screening (i.e., regular access examination
at hemodialysis unit, monitoring of venous pressure and access
flow). Group 2 was screened only traditionally (without ultra-
sound). Interventions of suspected stenoses were indicated by
nephrologists, vascular surgeon, and, in group 1, also by ultra-
sonography. Classic ultrasound criteria for significant stenosis
were used, even if the access flow had not been decreased. The
mean follow-up lasted 392 ± 430 days.
Results. Groups were similar with respect to age, gender,
diabetes status, and number of previous abandoned accesses.
Group 1 had significantly longer access patency (P < 0.001).
Number of interventions per graft was 2.1 ± 1.8 and 1.3 ± 1.0
in group 1 and group 2.
Conclusions. Regular screening duplex Doppler ultrasonog-
raphy results in significantly longer PTFE graft patency due to
early detection of access stenosis and, thus, more frequent elec-
tive interventions of access stenoses.
Polytetrafluoroethylene (PTFE) dialysis grafts have
shorter longevity than native arteriovenous fistulas [1].
Thrombosis of PTFE grafts continues to be a major
source of morbidity in hemodialysis patients [2]. In Euro-
pean countries, implantation of PTFE grafts remains to
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be a method of second choice. It is used when the creation
of native arteriovenous fistula is not possible, especially
due to lack of patent subcutaneous veins. The use of PTFE
graft is therefore significantly associated with higher risk
of cardiovascular disease, as characterized by older age,
higher body mass index, diabetes mellitus, and signs of pe-
ripheral vascular disease [3]. In the United States, where
the use of PTFE grafts is considerably higher, subjects
with this type of vascular access have higher mortality
than subjects with native arteriovenous fistulas [4].
Failure of vascular access, either with inadequate blood
flows or by clotting, results in the need of emergent per-
cutaneous or surgical intervention, which have poorer re-
sults than elective procedures. In some cases, placement
of a temporary dialysis access is necessary. Failure of vas-
cular access is usually preceded by development of access
stenosis. Therefore, several monitoring techniques have
been developed to forecast graft failure. These especially
include monitoring of dynamic venous pressure, mea-
surement recirculation, and access flow [5]. Best vascular
access care is summarized by Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines. These guidelines
are followed worldwide in developed countries, including
our country.
To compare longevity of vascular accesses between var-
ious centers, primary and secondary patency rates are
calculated. Primary patency is defined as the functional
access patency until any type of intervention; secondary
patency is defined as the functional access patency until
either final failure or the access is abandoned. In a meta-
analysis published recently by Huber et al [1], secondary
(cumulative) patency rates of PTFE grafts were as low as
76% at 6 months, and 55% at 18 months. Thus, placement
of PTFE graft is not a long-term solution for subjects with
lack of patent peripheral veins, and, often with history
of repeated closure of previous accesses. More effective
screening techniques for in-time detection of imminent
closure are needed.
Duplex Doppler ultrasonography has been repeatedly
proven as an accurate method for diagnosing access com-
plications in comparison to access angiography [6, 7].
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Although it is a simple, cheap, and accurate method,
duplex Doppler ultrasound access monitoring has not
been yet widely established. DOQI guidelines [5] support
the use of ultrasound only partially (evidence/opinion
level) because no clear evidence of prolongation of ac-
cess patency after ultrasound examinations has been
suggested. We hypothesized that regular duplex Doppler
ultrasound screening for access stenoses, together with
their sooner treatment, would prolong PTFE graft pa-
tency. To prove it, we performed a randomized, prospec-
tive study of PTFE grafts survival, where 1 group of
patients was screened traditionally (without ultrasound),
and the other also by regular ultrasound examina-
tions every 3 months, which was added to traditional
screening.
METHODS
This randomized prospective study was performed in
an unselected population of hemodialysis subjects be-
tween the years 1999 and 2004. Patients indicated for
creation of vascular access with PTFE graft located in
the upper extremity (as judged by the surgeon) were con-
secutively included into this study. All subjects received
6 mm Gore-tex stretch PTFE grafts in the Department
of Cardiovascular Surgery, General University Hospital
in Prague. The percentage of access types was as follows:
42% subjects received direct graft originating at the ra-
dial artery, 36% had antebrachial loop, in 20%, PTFE
started at the brachial artery, and 2% got PTFE loop
between subclavian vessels. Before access creation, pa-
tients were randomized into 2 groups: subjects in group 1
were regularly examined by duplex Doppler ultrasonog-
raphy every 3 months, while subjects in group 2 were
screened without the use of ultrasound. Age, gender, di-
abetes status, and number of previous abandoned or non-
maturated accesses were recorded. All subjects in both
groups were regularly screened for possible access com-
plications, including dynamic venous pressure, recircu-
lation, and blood flow monitoring, as guided by DOQI
guidelines in their hemodialysis units. Patients came from
25 hemodialysis units. Moreover, the vascular surgeon
examined both groups at a regular basis 3 to 4 times per
year. In both groups, fistulography was indicated either
by nephrologist or by vascular surgeon if access dysfunc-
tion was suspected. It was the case in the following condi-
tions: abnormal physical findings (conversion of thrill to
pulse, intensification of bruit at certain sites, edema of the
extremity bearing the vascular access), prolonged bleed-
ing after needle withdrawal, elevation of venous pressure
(above 140 mm Hg at 200 mL/min flow or trend to pres-
sure increase), decrease of access flow for more than 25%
or values below 600 mL/min, abnormal recirculation mea-
surements, and unexplained decrease in measurement of
dialysis dose. Specific indications guided by ultrasonog-
raphy are listed below. Secondary patency rates were cal-
culated and shown as Kaplan Meier curves. Secondary
patency was defined as the time until the graft was aban-
doned either due to irreversible thrombosis or due to
graft infection.
The local Ethical committee approved this study, and
all subjects signed informed consent.
Ultrasonography
Examinations were performed directly by an experi-
enced doctor with use of a linear array 7.5 MHz ul-
trasound probe Hewlett Packard SONOS 2000 device
until the year 2002, then by linear ultraband (3–11 MHz)
transducer of Phillips SONOS 5500 device. Examinations
started at the axillary artery, followed by the brachial and
antebrachial arteries. First, careful morphologic and color
Doppler examinations of brachial, ulnar, and radial arter-
ies were performed. Then, the feeding artery was assessed
by spectral pulse-wave Doppler imaging of the blood flow
at suspected sites identified by color Doppler mapping.
Detailed examinations of the arteries were followed by
inspection of PTFE graft, including calculation of blood
flow (mL/min). Blood flow was calculated by the internal
software of the ultrasound device according to the follow-
ing relation: Qa = p .r2.vmean, where Qa = access flow, r =
access radius, vmean = mean time averaged velocity rep-
resenting mean velocity of flowing blood layers during
cardiac cycle. Mean value of 3 calculations was accepted.
We have validated this method against thermodilution
measurement [8, 9].
Special attention was given to venous anastomosis and
adjacent segment of outflow vein, where stenoses are
mostly located. Then we followed the outflow vein up
to the subclavian vein. More than doubling of the peak
systolic blood flow velocity compared with unaffected
segment was used as a criterion of significant stenosis
if combined with stenosis in B mode. The exception was
in the arterial anastomosis, which was examined only by
B mode because high-flow velocity is a normal pattern
in this site. Ultrasound access examination is highly sen-
sitive and specific for both identification of stenoses and
calculation of blood flow, as shown previously [6, 7]. In
our hands, ultrasonography has 85% sensitivity and 94%
specificity compared with fistulography [6].
Ultrasound-guided indications to fistulography and/or
percutaneous or surgical treatment procedure were the
following: (1) finding of “significant” stenosis (inflow
artery, PTFE, or outflow vein) as defined above, with or
without decrease of blood flow; and (2) finding of stenoses
which did not seem significant, but were associated with
>25% decrease of access flow. In case of uncertainty of
stenosis significance, an arbitrarily defined residual diam-
eter less than 2.0 mm was the additional indication to fis-
tulography. Subjects with indeterminate findings (i.e., the
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Table 1. Characterization of studied groups
Group 1 Group 2
Age years 58.7 ± 14.2 58.3 ± 13.9
% Female 57 55
% Diabetic 53 51
Number of previous failed accesses 1.4 ± 1.6 1.3 ± 1.6
Group 1, subjects screened by ultrasound; group 2, subjects screened only
traditionally.
presence of only 1 of the aforementioned criteria) were
reexamined after 4 to 6 weeks by ultrasound. Similarly,
absolutely normal findings (high flow, no intimal hyper-
plasia, and no stenosis) were indicated for reexamination
after 4 months.
Statistics
All measured values were expressed as mean ± SD.
Baseline differences between groups were tested by un-
paired t test. P values < 0.05 were considered as sig-
nificant. Secondary patency rate between groups are
reported by Kaplan-Meier survival curves. Log-rank test
was used to compare differences between curves. The as-
sociation of ultrasound screening with secondary patency
rates was examined using univariate Cox regression anal-
ysis. To obtain a gross estimate of the influence of ac-
cess flow on access patency, we performed Kaplan-Meier
analysis of access patency in group 1, where the access
longevity was compared in the highest and in the quartile
of access flow.
RESULTS
We included 192 patients: 97 into group 1 and 92 into
group 2. These groups were similar, as shown in Table 1.
All subjects continued in the study except those who died.
The mean follow-up lasted 392 ± 430 days. Ultrasound
screening interval, primarily set to 3 months, varied be-
tween 1 and 5 months, depending on findings (defined in
Methods) and on compliance.
In hemodialysis units, 100% of patients had monitor-
ing of dynamic venous pressure; access flow measure-
ment was performed in 46% of subjects in group 1, and
in 49% in group 2 (90% of measurements by thermodilu-
tion, 10% by ultrasound dilution), and recirculation was
measured in 86% and 85%, respectively.
Ultrasonographically screened subjects (group 1) had
significantly higher secondary patency rates (P < 0.001
by log-rank test). Significance appeared after 6 months of
follow-up (P value = 0.09 at 6 months, 0.045 at 12 months,
0.002 at 18 and 24 months, and later P < 0.001). Relative
risk of access failure in group 2 calculated by Cox univari-
ate regression analysis was 3.75 (95%CI 1.7–8.1). Number
of interventions per graft was 2.1 ± 1.8 and 1.3 ± 1.0 in
group 1 and group 2, respectively. Radiologic interven-
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Fig. 1. Cumulative PTFE graft patency in subjects screened only tra-
ditionally (USG−) and in subjects screened also by regular ultrasonog-
raphy (USG+).
tions (percutaneous transluminal angioplasty, stent im-
plantations to outflow veins, mechanical thrombolysis)
were considerably more frequent than surgical revisions
(96% vs. 4%). Twenty-six ultrasound examinations were
performed in group 2 subjects; they were indicated by
nephrologists in case of allergy to contrast agents, need
of examination of extraluminal masses, in patients who
refused repeated fistulography, and others.
In group 1, baseline access flow measured by ultra-
sonography was 769 ± 303 mL/min (median 718 mL/min).
In the absence of access stenosis, access flow remained
stable during follow-up, with the variability of ± 10%.
We observed significantly higher percentage of access sur-
vival within the first year in subjects with baseline access
flow values in the highest quartile compared to those in
the lowest quartile of access flow (P = 0.03), but later this
difference disappeared (P = 0.38).
DISCUSSION
This study has shown that regular ultrasound screening
together with more aggressive approach to the treatment
of PTFE graft stenoses results in significant prolongation
of secondary patency rate. To the best of our knowledge,
it is for the first time that regular use of ultrasound has
been proven as a method leading to longer access patency.
Prolonged access patency in subjects screened by ul-
trasonography might be explained by earlier diagnosis of
stenoses by combining flow calculation and morphologic
evaluation during ultrasound examinations. It was pre-
viously shown that elective treatment of access stenosis
prolongs access life when compared to repair after an ini-
tial episode of clotting [10]. Our results are in accord with
some previous studies, which identified ultrasonography
as a predictor of future access thrombosis. Decreased
access blood flow, as measured by duplex Doppler ul-
trasonography, was repeatedly proven to be a significant
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predictor of access failure [11, 12]. Stenosis detection
per se was a significant predictor of future thrombosis
of PTFE graft in the study of Strauch et al [13]. On the
contrary, in a larger study that included both PTFE grafts
and native fistulas, duplex ultrasonographic detection of
access stenosis was not a strong predictor of incipient
thrombosis [14].
Surprisingly, our patients had considerably lower ac-
cess flow than in other studies [15]. It was probably caused
by the fact that PTFE graft is a second choice type of
hemodialysis access in our country, and by higher propor-
tion of diabetic subjects in our study. Diabetic angiopa-
thy and mediocalcinosis prevents dilatation of the feed-
ing artery after access creation, with subsequent lower
access flow. Secondary patency rates were higher in sub-
jects with the highest quartile of access flow in compari-
son to those having access flow within the lowest quartile
of values. However, this difference disappeared during
follow-up longer than 1 year. It could be assumed that
low-flow access (for example 500 mL/min) is at higher risk
of thrombosis in case of significant stenosis than high-flow
access (1500 mL/min) because the fall of access flow is per-
centual, and in the former case, it could reach “critically
low” values. Regular visualization of the entire vascular
access could determine developing stenoses before they
cause hemodynamic changes. We believe that ultrasound
screening is particularly important in low-flow accesses,
such as in diabetic patients. It is of potential importance
also for subjects with congestive heart failure because
safer (lower) access flow could be maintained.
Although higher access flow has been linked to lower
incidence of access thrombosis, it may lead to heart
failure.
Our results of secondary patency rates in subjects who
were not regularly screened by ultrasound are compara-
ble with literary data. Sert et al [16] reported 12-month
secondary patency of PTFE grafts of 65%. In a meta-
analysis, Huber et al reported mean secondary patency
of 76% at 6 months and 55% at 18 months. Excellent
results were published by Hurlbert et al [17], who com-
pared 2 types of grafts—at 12 months, 87% to 96%, and
at 24 months, 78% to 87%, of accesses were patent. The
latter results are comparable with our patients screened
by regular ultrasonography.
The advantage of ultrasonography is that it is an accu-
rate method (with the exception of central lesions, such
as the medial part of subclavian vein/artery), which does
not have limitations typical for methods based on the
dysfunction hypothesis. This hypothesis states that steno-
sis causes graft dysfunction, and this dysfunction reliably
precedes and accurately predicts thrombosis [18]. Such
dysfunction is mirrored by increase of venous pressure,
or by decrease of access flow. Unfortunately, in praxis, the
dysfunction hypothesis might fail, and traditional moni-
toring programs may allow disappointingly large propor-
tion of grafts to thrombose [18], for example, in case of
thrombophilia or outflow vein branching. Vein branch-
ing could partially and temporarily compensate a steno-
sis of outflow vein. Such patients may have no change of
access flow or dynamic venous pressure increase. There-
fore, it is evident that the term “hemodynamically sig-
nificant stenosis” by imaging methods is wider than that
based on dysfunction hypothesis. As we have previously
shown, clinical diagnosis of access thrombosis with the
use of venous pressure and access flow monitoring has
a low sensitivity, but high specificity in comparison with
duplex Doppler ultrasonography [19].
Future research should be oriented on cost/benefit ra-
tio of this approach. We think that longer access patency
compensates higher cost, especially in subjects with de-
pleted sites for future creation of next vascular access.
A possible limitation is the fact that it was a study per-
formed in only 1 vascular access center. Absolute values
of secondary patency rates are probably higher than in
smaller centers [1]. Another limitation is that patients
came from 25 hemodialysis centers, so we did not con-
trol both the level and regularity of access monitoring by
traditional methods and, thus, it could be not optimal.
Advantage of this fact is that our study population more
exactly reflects routine care.
CONCLUSION
Regular ultrasonographic screening for access stenoses
together with their earlier treatment leads to significant
prolongation of cumulative patency. This approach is of
highest importance to subjects with depleted sites for next
accesses.
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